[go: up one dir, main page]

WO2008137552A3 - Anticorps anti-rage et procédés d'utilisation de ceux-ci - Google Patents

Anticorps anti-rage et procédés d'utilisation de ceux-ci Download PDF

Info

Publication number
WO2008137552A3
WO2008137552A3 PCT/US2008/062231 US2008062231W WO2008137552A3 WO 2008137552 A3 WO2008137552 A3 WO 2008137552A3 US 2008062231 W US2008062231 W US 2008062231W WO 2008137552 A3 WO2008137552 A3 WO 2008137552A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
rage
methods
rage antibodies
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/062231
Other languages
English (en)
Other versions
WO2008137552A2 (fr
Inventor
Su-Yau Mao
Bo Chen
Chew-Shun Chang
Jane Tian
Partha Chowdhury
Anthony Coyle
Gary Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of WO2008137552A2 publication Critical patent/WO2008137552A2/fr
Publication of WO2008137552A3 publication Critical patent/WO2008137552A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps qui se lient au RAGE et inhibent la liaison entre le RAGE et le HMGB1 complexés avec l'ADN CpG. Les anticorps de la présente invention et les compositions pharmaceutiques comprenant ceux-ci sont utiles à de nombreuses fins, par exemple, comme agents thérapeutiques contre une large plage de conditions caractérisées par la présence de complexes immuns d'ADN et/ou associés à l'expression d'un ou plusieurs gènes inductibles d'IFN de type I.
PCT/US2008/062231 2007-05-02 2008-05-01 Anticorps anti-rage et procédés d'utilisation de ceux-ci Ceased WO2008137552A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US91557807P 2007-05-02 2007-05-02
US60/915,578 2007-05-02
US94678407P 2007-06-28 2007-06-28
US60/946,784 2007-06-28
US98405407P 2007-10-31 2007-10-31
US60/984,054 2007-10-31

Publications (2)

Publication Number Publication Date
WO2008137552A2 WO2008137552A2 (fr) 2008-11-13
WO2008137552A3 true WO2008137552A3 (fr) 2009-01-08

Family

ID=39944203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/062231 Ceased WO2008137552A2 (fr) 2007-05-02 2008-05-01 Anticorps anti-rage et procédés d'utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008137552A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2558301C2 (ru) * 2009-10-09 2015-07-27 Санофи Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MX2009013194A (es) 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2308896A1 (fr) * 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
EP2319871A1 (fr) * 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
ES2717908T3 (es) 2010-06-14 2019-06-26 Lykera Biomed S A Anticuerpos S100A4 y usos terapéuticos de los mismos
EP3633381A3 (fr) 2013-12-05 2020-07-29 The Broad Institute, Inc. Compositions et procédés d'identification et de traitement de la cachexie ou de la pré-cachexie
RU2736299C2 (ru) 2015-03-31 2020-11-13 Медиммун Лимитед Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения
EP3822291A1 (fr) 2015-06-10 2021-05-19 The Broad Institute Inc. Anticorps, composés et écrans permettant l'identification et le traitement la cachexie ou pré-cachexie
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
WO2021089559A1 (fr) 2019-11-04 2021-05-14 Medimmune Limited Agent thérapeutique anti-il-33 pour le traitement de troubles rénaux
IL292443A (en) 2019-11-04 2022-06-01 Medimmune Ltd Methods for using IL-33 antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2558301C2 (ru) * 2009-10-09 2015-07-27 Санофи Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие

Also Published As

Publication number Publication date
WO2008137552A2 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008137552A3 (fr) Anticorps anti-rage et procédés d'utilisation de ceux-ci
WO2008100624A3 (fr) Anticorps contre erbb3 et leur utilisation
WO2011006915A3 (fr) Domaines variables uniques de liaison anti-albumine sérique améliorés
WO2009063965A1 (fr) Anticorps monoclonal capable de se lier à un gène non contrôlé (anexelekto) et son utilisation
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2013119966A3 (fr) Anticorps et autres hétéromultimères monocaténaires
WO2013023732A3 (fr) Ternésite utilisée comme activateur pour des substances aux propriétés hydrauliques latentes et pouzzolaniques
WO2012019024A3 (fr) Molécules se liant à her3 et leurs immunoconjugués
WO2005100403A3 (fr) Anticorps diriges contre le recepteur de l'erythropoietine et utilisations associees
WO2014059442A8 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2009155180A8 (fr) Anticorps anti-il-6 et leurs utilisations
HK1207092A1 (en) Anti-hla-b*27 antibodies and uses thereof
MA32980B1 (fr) Proteines de liaison a la myostatine
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2010094722A3 (fr) Variants de liaison anti-albumine sérique améliorés
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008097439A3 (fr) Anticorps contre des maladies auto-immunes pour traiter le pemphigus
WO2010111690A3 (fr) Compositions de polymérase et procédés
WO2012088302A3 (fr) Protéines de liaison à une demi-immunoglobuline et leurs utilisations
WO2009058383A3 (fr) Ligand
WO2011133886A3 (fr) Production de protéines hétéromultimères
WO2010033279A3 (fr) <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
WO2010006173A3 (fr) Complexe minéral-acide aminé-polysaccharide
WO2008063776A3 (fr) Anticorps de la lymphotoxine-alpha

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08747355

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08747355

Country of ref document: EP

Kind code of ref document: A2